Navigation Links
American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows
Date:2/12/2009

Dr. Ruano's Pioneering Contributions to Personalized Medicine Cited for Honor

HARTFORD, Conn. and WASHINGTON, Feb. 12 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., was inducted into the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows today at a ceremony in Washington, DC at the National Academy of Sciences. Recipients of this honor are chosen for exceptional leadership and achievements in medical and biological engineering. Dr. Ruano is President and Chief Executive Officer of Genomas Inc., Director of Genetics Research at Hartford Hospital, and Adjunct Professor in the medical faculties at George Washington University and at the University of Puerto Rico.

At AIMBE (www.aimbe.org), the College of Fellows leads the way in technological advancement, advocating for public policies facilitating progress in medical and biological research and development to benefit the public. As the array of companies and entire industries based on biotechnology and bioengineering has expanded rapidly, AIMBE Fellows have assumed leading roles in both their R&D and management functions, driving the movement of new medical technologies to patient care. Fellows hold numerous patents that have helped make medical and biological engineering a major economic force in the U.S., generating $200 billion in revenue annually and supporting thousands of high-paying jobs.

"I am very honored by this appointment to the AIMBE College of Fellows. Based on my experience at Genomas and Hartford Hospital, advancing DNA-Guided Medicine to clinical practice requires integration of molecular technologies, medical decision algorithms, and physician user interfaces. Such synthesis indeed is a feat of biomedical engineering," said Dr. Ruano. "I look forward to working with AIMBE and its fellows in this quest to bring personalized medicine to healthcare."

In his 25-year scientific and medical career, Dr. Ruano has developed systems for DNA-guided medicine based on genomics, nanoscience, and clinical informatics. At Genomas, he has pioneered physiotypes based on multi-gene markers and bioclinical algorithms for the prediction of human drug response and DNA-guided medicine in patient care.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.net for more information.


'/>"/>
SOURCE Genomas
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
2. New General Manager, Transition to New Raleigh Offices Highlight Datatrials Expansion of North American Operations
3. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
4. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
5. American Oriental Bioengineering Comments on Recent Property Purchase
6. Tips from the journals of the American Society for Microbiology
7. Elsevier Introduces The American Journal of Medicine Blog
8. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
9. Transgenomic Receives Accreditation From College of American Pathologists
10. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
11. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):